Crinetics Pharmaceuticals, Inc.
DE ˙ DB ˙ US22663K1079
27,79 € ↑0,30 (1,09%)
2026-06-04
DEL PRIS
SecurityDE:6Z4 / Crinetics Pharmaceuticals, Inc.
InstitutionJanus Henderson Group Plc
Latest Disclosed Ownership4,520,251 shares
Latest Disclosed Value $ 164,227,195
Janus Henderson Group Plc reports 1.79% increase in ownership of 6Z4 / Crinetics Pharmaceuticals, Inc.

On May 18, 2026 - Janus Henderson Group Plc filed a 13F-HR/A form disclosing ownership of 4,520,251 shares of Crinetics Pharmaceuticals, Inc. (DE:6Z4) valued at $133,799,430 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 4,440,691 shares of Crinetics Pharmaceuticals, Inc.. This represents a change in shares of 1.79% during the quarter. The current value of the position is $125,617,775 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-18 2026-03-31 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 4,520,251 79,560 1.79 164,227 -20.51 0.0277
2026-05-15 2026-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 4,520,251 79,560 164,227 0.0305
2026-02-17 2025-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 4,440,691 581,900 15.08 206,604 28.57 0.0925
2025-11-14 2025-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 3,858,791 448,471 13.15 160,696 63.87 0.0734
2025-08-14 2025-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 3,410,320 -14,122 -0.41 98,063 -17.52 0.0481
2025-05-15 2025-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 3,424,442 629,001 22.50 118,895 -16.80 0.0652
2025-02-14 2024-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,795,441 365,991 15.06 142,902 15.12 0.0726
2024-11-14 2024-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,429,450 -26,211 -1.07 124,131 12.88 0.0635
2024-08-14 2024-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,455,661 477,489 24.14 109,970 18.85 0.0589
2024-05-15 2024-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,978,172 1,434,909 264.13 92,526 378.76 0.0505
2024-02-14 2023-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 543,263 -45,115 -7.67 19,327 10.60 0.0115
2023-11-14 2023-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 588,378 117,642 24.99 17,475 106.18 0.0114
2023-08-14 2023-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 470,736 54,484 13.09 8,476 26.74 0.0053
2023-05-15 2023-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 416,252 9,988 2.46 6,687 -9.98 0.0044
2023-02-14 2022-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 406,264 216,416 113.99 7,429 99.04 0.0053
2023-01-13 2022-09-30 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 189,848 189,848 3,732 0.0028
2022-11-14 2022-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 189,848 189,848 3,732 0.0009
2020-08-14 2020-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 0 -491,691 -100.00 0 -100.00
2020-05-14 2020-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 491,691 2,819 0.58 7,228 -41.07 0.0050
2020-02-18 2019-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 488,872 -7,788 -1.57 12,266 64.20 0.0063
2019-11-14 2019-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 496,660 -2,882 -0.58 7,470 -40.19 0.0040
2019-07-31 2019-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 499,542 11,175 2.29 12,489 12.36 0.0068
2019-04-30 2019-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 488,367 -41,459 -7.83 11,115 -30.05 0.0062
2019-02-06 2018-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 529,826 5,082 0.97 15,889 5.69 0.0101
2018-11-09 2018-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 524,744 524,744 15,034 0.0080
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.